Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

Impact of taxanes after PD-1 blockade exposure in advanced esophageal squamous cell carcinoma

Published:2024-09-02 Issue: Volume: Page:
ISSN:1612-9059
Container-title:Esophagus
language:en
Short-container-title:Esophagus

Author:

Shiraishi Kazuhiro,Takeyasu Yuki,Yamamoto Shun,Oshima Kotoe,Imazeki Hiroshi,Hirano Hidekazu,Okita Natsuko,Shoji Hirokazu,Honma Yoshitaka,Iwasa Satoru,Takasima Atsuo,Kato Ken^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10388-024-01085-5.pdf

Reference24 articles.

1. Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol. 2016;31(6):1141–6.

2. Adenis A, Bennouna J, Etienne PL, et al. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: a randomised phase II trial (E-DIS). Eur J Cancer. 2019;111:12–20.

3. Iizuka T, Kakegawa T, Ide H, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol. 1992;22(3):172–6.

4. Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31(9):419–23.

5. Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011;67(6):1265–72.